Hematology Pills is a new format based on monthly discussions between Prof. Robin Foà (Rome) and Dr. Filippo Milano (Seattle). Each episode explores the latest breakthroughs in gene therapy, immunotherapy, and clinical innovation, while addressing also ethical and practical challenges that shape the field. Our podcast offers a clear and compelling look at the evolving landscape of blood disorders and treatments for hematologists, researchers and healthcare professionals. Stay informed, inspired, and connected with Hematology Pills – a source off hematology updates, one episode at a time.
Hematology Pills
Claim This Podcastby Mattioli Health
5.0(14 reviews)
17 episodes
Updated Daily
Accepts GuestsHas SponsorsLocation 🇮🇹
19
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality25
Social0
YouTube0
Engagement32
Podcast Overview
Hematology Pills is a new format based on monthly discussions between Prof. Robin Foà (Rome) and Dr. Filippo Milano (Seattle). Each episode explores the latest breakthroughs in gene therapy, immunotherapy, and clinical innovation, while addressing also ethical and practical challenges that shape the field. Our podcast offers a clear and compelling look at the evolving landscape of blood disorders and treatments for hematologists, researchers and healthcare professionals. Stay informed, inspired, and connected with Hematology Pills – a source off hematology updates, one episode at a time.
Language
🇺🇲
Publishing Since
2/26/2025
Unlock The Full Podcast Authority Score Report
See how your podcast performs across key metrics
19
Podcast Authority
BetaPoorBased on show quality, social media presence, reviews, charts, and more
Quality25
Social0
YouTube0
Engagement32
6
Excellent Areas
0
Good Performance
13
Growth Opportunities
excellent
Episode Length
19 minutes
Performing excellently!
needs improvement
Publishing Consistency
Every 22 days
Recommendations available
Unlock the full report to see detailed tips
+16 More Metrics
Unlock comprehensive insights including:
- • YouTube presence analysis
- • Social media reach metrics
- • RSS compliance scoring
- • Podcast 2.0 features
- • Technical standards
What's Included in Your Full Report
Detailed Analytics
- Complete breakdown of all 19 authority metrics
- Personalized recommendations for each metric
- Industry benchmarks and comparisons
- Technical RSS feed analysis and compliance scoring
Growth Strategies
- Step-by-step action plans for improvement
- Quick wins to boost your score immediately
- Pro tips from successful podcasters
Get your free podcast insights report
See how your show performs across every key metric
Instant delivery
No spam
Attract Better Guests
High authority scores make your podcast more attractive to industry leaders and influencers who want to appear on credible shows.
Secure Sponsorships
Sponsors look for podcasts with proven authority and engagement. Your score demonstrates your podcast's value to potential partners.
Grow Your Audience
Understanding your strengths and weaknesses helps you make data-driven decisions to expand your listener base effectively.
2 verified phone numbers on file for Hematology Pills
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
Recent Episodes
July 20, 2026
From CML to AML: Precision Medicine, Global Access, and the Future of Leukemia Care – A Dialogue Between Robin Foà, Filippo Milano and Jerald Radich
<p>In this episode, Prof. Robin Foà, Dr. Filippo Milano, and Dr. Jerald Radich revisit the extraordinary journey of chronic myeloid leukemia (CML), one of the greatest success stories in modern hematology and the disease that transformed precision medicine from concept to clinical reality.</p><p>The discussion retraces the evolution of CML treatment, from an era when bone marrow transplantation represented the only curative option to the revolutionary introduction of tyrosine kinase inhibitors (TKIs), which have dramatically changed the natural history of the disease. Today, most patients receiving TKI therapy can expect a life expectancy comparable to that of the general population, making CML the prototype of targeted cancer therapy.</p><p>The conversation also highlights the global impact of scientific innovation through the partnership with The Max Foundation, an initiative that has expanded access to molecular diagnostics and lifelong TKI treatment for tens of thousands of patients in low- and middle-income countries. By combining innovative diagnostic strategies with worldwide collaboration, the program has demonstrated that precision medicine can become a global reality rather than a privilege limited to high-income healthcare systems.</p><p>Looking toward the future, the episode explores MyeloMatch, the largest precision medicine trial ever conducted in acute myeloid leukemia (AML). By integrating rapid molecular profiling, next-generation sequencing, and targeted therapies, the initiative aims to redefine frontline AML treatment while advancing increasingly sensitive measurable residual disease (MRD) assessment. The discussion examines both the promise and the challenges of applying precision medicine to a biologically complex disease such as AML, where molecular diversity continues to shape prognosis and therapeutic decision-making.</p><p>A compelling conversation on how decades of scientific discovery have reshaped leukemia care—demonstrating how precision medicine, global collaboration, and molecular innovation continue to redefine the future of hematology.</p>
June 19, 2026
The Next Chapter of Cord Blood Transplantation: Harnessing Immune Responses to Improve Transplant Outcomes – A dialogue between Robin Foà and Filippo Milano
<p>In this episode, Prof. Robin Foà and Prof. Filippo Milano reflect on a groundbreaking phase two study out of Seattle that introduces a novel and highly effective approach to cord blood transplantation. Unlike traditional double cord blood transplants, which have historically been hindered by severe complications when T-cells from both units interact, this new methodology overcomes these major disadvantages to reshape patient outcomes.</p><p>The conversation delves into the biological mechanics of this pioneering technique. Prof. Milano details how his research team successfully combined a single matched cord blood unit with an off-the-shelf product made from a pool of six to eight different units. By meticulously CD34-selecting and expanding these pooled cells for 14 days on a Notch platform, they created a therapeutic product rich in CD34 and monocytic cells, yet completely lacking T-cells.</p><p>A major theme of the discussion is the striking clinical success of this trial. Among approximately 30 patients, the approach yielded a 96% overall survival rate and a remarkable 0% incidence of acute grade 3 and 4 Graft-Versus-Host Disease (GVHD). Beyond survival metrics, the episode explores a fascinating biological phenomenon observed between day 7 and 10 post-transplant: a massive spike in active CD8 lymphocytes. Single-cell RNA sequencing revealed that these monoclonal cells originated from the matched unit, reacting to the mixed HLA of the pooled product. Prof. Milano highlights ongoing research using mouse models to see if this immune response can be predictably directed to enhance the Graft-Versus-Leukemia (GVL) effect, which would be especially beneficial for patients with active disease.</p><p>The debate then turns to the broader structural challenges facing the field today. With the overall number of cord blood transplants declining and public banks shrinking—even halting collections in major cities like New York—Prof. Milano strongly advocates for the preservation of this critical resource. Cord blood remains a vital, immediately available, pre-typed stem cell source, a readiness that proves essential during unexpected global emergencies like pandemics.</p><p>As the episode closes, the speakers look ahead to the future, discussing plans to test this pooled cell product in mismatched related haploidentical transplants. This dialogue is a candid examination of both scientific ingenuity and systemic challenges—a reminder that persistent innovation and dedicated research continue to push the boundaries of what is possible in the field of hematopoietic stem cell transplantation.</p>
May 20, 2026
Ph+ ALL without chemotherapy: when TKIs reshape the immune response – A dialogue between Robin Foà, Filippo Milano e Michela Ansuinelli
<p>In this episode, Prof. Robin Foà and Dr. Filippo Milano explore the evolving treatment landscape of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), focusing on the transition from intensive chemotherapy and transplantation toward targeted therapies combined with immunotherapy. What emerges from the discussion is not only a new therapeutic strategy, but a deeper understanding of how these treatments profoundly reshape the immune system.</p><p>The conversation centers on the biological effects of combining tyrosine kinase inhibitors with blinatumomab, revealing unexpected patterns of immune activation. Patients treated with Dasatinib showed significant expansion of T cells and NK cells, while the addition of blinatumomab further enhanced immune responses and reduced immunosuppressive regulatory T cells. Particularly striking was the observation that patients achieving early complete molecular responses also displayed the strongest immune modulation, suggesting a direct link between immune activation and clinical outcome.</p><p>The episode also examines the differences between Dasatinib and Ponatinib. While Dasatinib appears to induce a broad quantitative immune response, Ponatinib seems to act more through qualitative and phenotypic changes, promoting maturation and functional activity of immune effector cells. These findings highlight how different TKIs may interact with the immune system in distinct ways, opening new perspectives for individualized treatment strategies.</p><p>Looking ahead, the discussion expands to the broader role of the tumor microenvironment, checkpoint inhibition, and CAR-T cell therapy, emphasizing how future advances in Ph+ ALL will increasingly depend on understanding the dialogue between leukemia cells and host immunity at the single-cell level.</p><p>A thoughtful exploration of how targeted therapy and immunotherapy are redefining the concept of leukemia treatment—moving beyond disease control toward immune-driven eradication of residual disease.</p><p><br /></p>
17 total episodes available
Recent guests on Hematology Pills
Guests from recent episodes — sign up to see every guest that has ever appeared on this show.
Robin Foà
Guest
Filippo Milano
Guest
Sabina Chiaretti
Guest
Professor Robin Foà
Guest
Dr Filippo Milano
Guest
Deep-dive analytics for Hematology Pills
Frequently asked questions
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
- What is Hematology Pills?
- How often does this podcast release new episodes?
This podcast updates daily.
- Where can I listen to this podcast?
This podcast is available on 4 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
- Does this podcast accept guests?
Yes, this podcast regularly features guests.
Legal Disclaimer
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.